Bitopic inhibitors target ABL1 and EGFR kinases with enhanced efficacy

A design approach enables the development of bitopic inhibitors for ABL1 and EGFR kinases.

Published 3h1 sourceImportant

≈ 18sSpeed

The fact

These molecules show enhanced activity against resistance mutations and reduced off-target effects.

They could improve treatments for cancers resistant to current therapies.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on September 23, 2026